Healthcare Realty Trust Incorporated (HR) Guidance & Earnings Results

On 2026-07-30 Healthcare Realty Trust Incorporated raised guidance: "FY2026 Normalized FFO guidance raised to $1.62-$1.66 per share (diluted) from $1.60-$1.64 per share; FY2026 Same Store Cash NOI growth guidance raised to 4.25%-5.00% from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HRHealthcare Realty Trust IncorporatedFollow HR — free

REIT - Healthcare Facilities · Real Estate

—

Price chart with a free account

Market cap: 6.2B
P/E TTM: —
Dividend yield: 5.3%
52-week: —
Next earnings: 29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
30 Jul 26	Raised	FY2026 Normalized FFO guidance raised to $1.62-$1.66 per share (diluted) from $1.60-$1.64 per share; FY2026 Same Store Cash NOI growth guidance raised to 4.25%-5.00% from 3.75%-4.75% · full year
30 Apr 26	Raised	FY2026 Normalized FFO per share (diluted) raised to $1.59-1.65 from prior (midpoint +$0.01); Same Store Cash guidance increased · full year
30 Oct 25	Raised	Normalized FFO guidance raised to $1.59-$1.61; same store NOI growth to 4.00%-4.75% · full year
31 Jul 25	Raised	FY2025 NFFO guidance raised to $1.57-$1.61 per share from $1.56-$1.60 per share · full year

Healthcare Realty Trust Incorporated — questions

What guidance did Healthcare Realty Trust Incorporated give?: On 2026-07-30: "FY2026 Normalized FFO guidance raised to $1.62-$1.66 per share (diluted) from $1.60-$1.64 per share; FY2026 Same Store Cash NOI growth guidance raised to 4.25%-5.00% from 3.75%-4.75%"
When does Healthcare Realty Trust Incorporated report earnings?: Healthcare Realty Trust Incorporated's next earnings report is expected on 2026-10-29.

Every figure on this page comes from Healthcare Realty Trust Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.